PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.

Ulla Nuutinen, Niina Simelius, Antti Ropponen, Jonna Eeva, Mikko Mättö, Mine Eray, Riikka Pellinen, Jarmo Wahlfors, Jukka Pelkonen

Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Kuopio, Finland. ulla-maija.nuutinen@uku.fi

Leukemia research 2009 Jun

filter terms:

Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to activate type I apoptotic pathway in type II cells. However, an inhibitor of IKK did not switch apoptosis to type I pathway in type II cells, indicating that NF-kappaB might not be responsible for the switch.

Citation

Ulla Nuutinen, Niina Simelius, Antti Ropponen, Jonna Eeva, Mikko Mättö, Mine Eray, Riikka Pellinen, Jarmo Wahlfors, Jukka Pelkonen. PDTC enables type I TRAIL signaling in type II follicular lymphoma cells. Leukemia research. 2009 Jun;33(6):829-36